Takeaway

• The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting conditional marketing authorization for ciltacabtagene autoleucel, a new gene therapy for relapsed and refractory multiple myeloma (R/R MM).

Why this matters

• Ciltacabtagene autoleucel is a chimeric antigen receptor (CAR)-T cell drug...